Welcome to Markets Desk, your midday read on the stories moving markets and minds.
Novo Nordisk is getting a real-world boost today as new data shows patients who switched from Wegovy injections to the oral pill version continued losing weight without interruption. That's a meaningful signal for the obesity drug market, suggesting the pill format isn't a step down in efficacy — and could meaningfully expand the addressable patient pool for Novo going forward.
Shifting to fixed income, a strategist who spent years warning against Treasury bonds is now turning bullish, and his reasoning is straightforward: five-point-two-five percent yields finally offer what he calls a big fat cushion. After years of artificially suppressed rates distorting return expectations, he sees five percent on Treasuries and six percent on equities as the new realistic baseline — and he likes what he sees.
And in biotech, FibroBiologics is catching a bid after the European Patent Office granted the company a key patent covering its fibroblast therapeutic technology. For a clinical-stage name, European IP protection is a genuine milestone — it expands the commercial runway and adds a layer of defensibility that investors in early-stage biotech tend to reward quickly.
That's the tape. Markets Desk, signing off the floor.
